ReNeuron Group plc Total Voting Rights (4657L)
03 Enero 2023 - 1:02AM
UK Regulatory
TIDMRENE
RNS Number : 4657L
ReNeuron Group plc
03 January 2023
ReNeuron Group plc
("ReNeuron", the "Group" or the "Company")
Total Voting Rights
At 31 December 2022, the Company had 57,173,760 Ordinary Shares
in issue, each carrying one voting right.
As the Company holds no ordinary shares in treasury, the figure
of 57,173,760 may be used by shareholders as the denominator for
the calculation by which they will determine if they are required
to notify their interest in, or a change in their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Iain Ross, Executive Chairman Via Walbrook PR
John Hawkins, Chief Financial
Officer
Liberum Capital Limited (NOMAD and
Joint Broker)
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking) +44 (0)20 3110 2000
Allenby Capital Limited (Joint +44 (0)20 3328 5656
Broker)
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Relations)
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407
804 654
About ReNeuron
ReNeuron is a UK based Proprietary Stem Cell derived Exosome
Technologies company, harnessing its unique stem cell technologies
to develop 'off the shelf' treatments for diseases with significant
unmet needs.
ReNeuron's stem cell derived proprietary Exosome Technology
platform offers a delivery mechanism for a variety of payloads such
as siRNA, mRNA, proteins, small molecules and genes. The Group has
a growing number of partner collaborations with Global Pharma,
Biotech and academic partners in this fast-expanding area of
scientific and commercial interest. ReNeuron also has the ability,
through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and
has the potential to produce exosomes with tissue specific
targeting ability.
The Group has out-licensed its CTX programme for stroke
disability and hRPC programme in retinitis pigmentosa to Fosun in
China and is looking to out-license both of these programmes in
other territories.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRGZGGMNFMGFZG
(END) Dow Jones Newswires
January 03, 2023 02:02 ET (07:02 GMT)
Reneuron (AQSE:RENE.GB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Reneuron (AQSE:RENE.GB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024